Bonnie Halpern-Felsher: Vaping, Alcohol Use & Other Risky Youth Behaviors In this episode, my guest is Dr
We offer Semaglutide a GLP-1 receptor agonistas part of our evidence-based approach to weight management and metabolic health
Recognizing this mechanism makes it easier to select dietary and behavioral changeslike smaller, lower-fat meals and adjusted meal timingthat can blunt the nausea while preserving clinical benefit
In a 2-year CV outcomes trial with semaglutide injection involving patients with type 2 diabetes mellitus and high CV risk, diabetic retinopathy complications (which was a 4-component adjudicated endpoint) occurred in patients treated with semaglutide injection (3%) compared to placebo (1.8%)
Gastric Emptying As GLP-1 receptor agonists slow gastric motility and can cause clinically meaningful gastroparesis, residual food or liquid may remain in the stomach
To support your progress: Regular follow-ups will ensure your experience remains comfortable and effective